Stock Market Impact: Merck shares rose 0.44% (ticker MRK+0.44%) following the FDA announcement, indicating immediate positive sentiment.
Listed Companies and Sectors: Merck & Co (pharmaceutical sector) received the orphan designation for its Keytruda (pembrolizumab) targeting neuroendocrine prostate cancer, a rare disease.
Investment Flows: No specific information on FDI/FPI or capital flows was provided.
Interest Rates, Inflation, and Liquidity: Not mentioned.
